Table 5.
Adjusted probabilities for 3-month mortality in propensity-matched patients.
| Risk factors | 3-month mortality |
|
|---|---|---|
| Adjusted odds ratio (95% CI) | p value | |
| ABSI | 1.11 (0.97–1.26) | 0.122 |
| SAPS II | 1.04 (1.03–1.06) | <0.001 |
| Acute kidney injury | 0.88 (0.37–2.00) | 0.756 |
| Acute respiratory distress syndrome | 0.86 (0.33–2.18) | 0.751 |
| Cholestatic liver injury with ketamine ≥10,000 mg | 9.92 (2.76–39.05) | 0.001 |
| No cholestatic liver injury with ketamine ≥10,000 mg | 0.43 (0.02–2.64) | 0.446 |
| Cholestatic liver injury with ketamine <10,000 mg | 0.90 (0.14–3.78) | 0.894 |
| Total sufentanil (mg): (0, 50] | 1.77 (0.54–5.71) | 0.340 |
| Total sufentanil (mg): (50, 1,500] | 0.58 (0.17–1.86) | 0.367 |
| Total sufentanil (mg): (1,500, 5,000] | 0.42 (0.08–1.98) | 0.281 |
| Total sufentanil (mg): (5,000, Inf] | 0.23 (0.04–1.36) | 0.110 |
| Total midazolam (mg): (0, 500] | 1.97 (0.68–5.92) | 0.216 |
| Total midazolam (mg): (500, 1,500] | 2.95 (0.61–14.37) | 0.177 |
| Total midazolam (mg): (1,500, Inf] | 1.31 (0.21–8.08) | 0.768 |
| Observations | 279 | |
Patient were matched (full matching) on the probability of receiving ketamine dose >1,000 mg according to severity of illness (ABSI and SAPS II scores), and organ failure (acute kidney injury, acute respiratory syndrome, and septic shock). Risks were computed with multivariate logistic regression models. Cholestatic liver injury corresponded to an increase of ALP ≥1.5 × ULN with a concomitant increase of serum GGT ≥3 × ULN and TBIL >ULN. The SAPS II ranges from 0 to 163, with higher scores indicating greater severity of illness. The ABSI ranges from 0 to 18, with higher scores indicating a greater probability of death after the burn injury.
ABSI, abbreviated burn severity index; ALP, alkaline phosphatase; TBIL, total bilirubin; GGT, gamma glutamyl transferase; Inf, infinite; SAPS II, Simplified Acute Physiology Score II; ULN, upper limit of normal.